Cargando…

Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer

Although subsets of patients with lung squamous cell carcinoma (LSCC) benefit from immunotherapy, there are few effective molecularly targeted treatments for LSCC. Fibroblast growth factor receptor (FGFR) inhibitors provide a therapeutic option for patients with LSCC harboring FGFR aberrations, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mäkinen, Netta, Meyerson, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617760/ https://www.ncbi.nlm.nih.gov/pubmed/37909331 http://dx.doi.org/10.1172/JCI174171

Ejemplares similares

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
por: Dutt, Amit, et al.
Publicado: (2011)

FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies
por: Weeden, CE, et al.
Publicado: (2015)

Lung squamous cell carcinoma exhibits a targetable glucose dependency unique among non-small cell lung cancers
por: Goodwin, Justin, et al.
Publicado: (2017)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer
por: Malchers, Florian, et al.
Publicado: (2023)

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
por: Mäkinen, Netta, et al.
Publicado: (2021)

Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors
por: Mäkinen, Netta, et al.
Publicado: (2022)

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2019)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors
por: Zhang, Zhouwei, et al.
Publicado: (2020)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2022)

Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer
por: Elakad, Omar, et al.
Publicado: (2022)

Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
por: Kono, Michihisa, et al.
Publicado: (2022)

Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2‐FGFR1 autocrine loop
por: Cen, Mengyuan, et al.
Publicado: (2018)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
por: Hibi, Masaaki, et al.
Publicado: (2016)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma
por: Kwon, Dohee, et al.
Publicado: (2016)

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway
por: Ji, Wenxiang, et al.
Publicado: (2016)

FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
por: Szymczyk, Jakub, et al.
Publicado: (2021)

Mutational Status of FGFR3 in Oral Squamous Cell Carcinoma
por: Motahhary, P., et al.
Publicado: (2012)

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
por: Fumarola, Claudia, et al.
Publicado: (2017)

Application of mucosal functional genomics to childhood undernutrition and stunting: Insights into mechanisms and targeted interventions
por: Denson, Lee A.
Publicado: (2021)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non‐small cell lung cancer
por: Theelen, Willemijn SME, et al.
Publicado: (2016)

Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
por: Schildhaus, Hans-Ulrich, et al.
Publicado: (2012)

The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data
por: Wang, Yang, et al.
Publicado: (2015)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
por: Cowell, John K., et al.
Publicado: (2021)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer
por: Reale, Maria Lucia, et al.
Publicado: (2020)

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
por: Zhou, Zhen, et al.
Publicado: (2021)

Novel insights into circular RNA regulation in arsenic-exposure-induced lung cancer
por: Ao, Xiang, et al.
Publicado: (2022)

FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma
por: Chen, Tao, et al.
Publicado: (2021)

Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells
por: Wang, Jun, et al.
Publicado: (2014)

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer
por: Packer, Leisl M., et al.
Publicado: (2019)

SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas
por: Zheng, Shanbo, et al.
Publicado: (2015)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u6h5t3li02ugclsleafqv0bli4